🫀 Dual Antiplatelet Therapy Mechanism Simulator

Resting Platelet Signaling Before Any Antiplatelet Drug

A short placeholder overview of normal platelet activation biology.

• 100%: COX-1 activity (placeholder baseline value)
• 100%: P2Y12 activity (placeholder baseline value)
• High: TXA2 output (placeholder synthesis level)
• Full: Aggregation (placeholder response level)

How platelets normally activate and aggregate

Placeholder short description of collagen/ADP/thromboxane activation loop.

Aspirin Irreversibly Acetylates the COX-1 Active Site

A short placeholder overview of aspirin acetylating serine-530 on COX-1.

• Irreversible: Acetylation (placeholder mechanism note)
• ~30 min: Onset (placeholder timing value)
• Platelet lifespan: Duration (placeholder ~10 days)
• 75-100mg: Dose typical (placeholder daily dose)

Mechanism of COX-1 acetylation by aspirin

Placeholder short description of serine acetylation blocking arachidonic acid access.

Loss of Thromboxane A2 Weakens Platelet Recruitment

A short placeholder overview of downstream TXA2 pathway suppression.

• Suppressed: TXA2 synthesis (placeholder outcome)
• Reduced: TXA2 receptor signal (placeholder outcome)
• Reduced: Vasoconstriction (placeholder outcome)
• Weakened: Recruitment (placeholder outcome)

Downstream effect of losing thromboxane A2

Placeholder short description linking COX-1 blockade to reduced amplification.

Clopidogrel and Ticagrelor Block the ADP Receptor

A short placeholder overview of P2Y12 receptor antagonism.

• Irreversible: Clopidogrel type (placeholder prodrug note)
• Reversible: Ticagrelor type (placeholder direct-acting note)
• P2Y12 receptor: Target (placeholder ADP receptor)
• Blocks amplification: Effect (placeholder outcome)

Mechanism of P2Y12 receptor antagonism

Placeholder short description of ADP-driven activation loop being interrupted.

Combining Both Pathways for Stronger Platelet Suppression

A short placeholder overview of combined dual antiplatelet therapy benefit.

• High: Combined suppression (placeholder synergy note)
• Lowered: Stent thrombosis risk (placeholder clinical benefit)
• Increased: Bleeding risk (placeholder tradeoff note)
• Post-PCI: Typical use (placeholder clinical context)

Why dual antiplatelet therapy is used together

Placeholder short description of synergistic dual-pathway platelet inhibition.

Placeholder key takeaway about DAPT balancing thrombosis and bleeding risk.